MIRM Mirum Pharmaceuticals, Inc. Insider Trading

CFO Eric Bjerkholt sells 5,000 shares (5.0K) for $611,273.24 under pre-arranged 10b5-1 plan

Eric Bjerkholt, Chief Financial Officer of Mirum Pharmaceuticals, executed 4 separate sales totaling 5,000 shares for $611,273.24 on 2026-07-06, reducing his holdings from 47.2K to 42.2K shares (-10.6%). This transaction was completed under a pre-arranged 10b5-1 trading plan adopted on 2026-03-09, meaning the sales were scheduled rather than discretionary. At $122.25 blended average price, the sale occurred below the current price of $128.57 and near the 52-week high of $129.00. While his cross-ticker track record shows 2 prior sales with a 90-day average return of -2.8%, his same-ticker history at MIRM includes a prior sell on 2026-03-16 that returned +4.8% over 30 days and +8.0% over 90 days, suggesting his recent sales at this company have generally preceded modest gains. Given that this transaction is scheduled under a 10b5-1 plan rather than reflective of current discretionary decision-making, and the company remains unprofitable despite strong annual revenue growth of +54.7%, the sale provides limited signal regarding the CFO's present conviction about near-term stock performance.

CEO Christopher Peetz sells 20,000 shares at $121.65–$124.79; retains 194,309 shares plus 108,487 options via scheduled 10b5-1 plan.

Christopher Peetz, CEO of Mirum Pharmaceuticals, executed four separate sales totaling 20,000 shares (20.0K shares) on 2026-07-06 for $2,445,382.04 ($2.4M) at prices ranging from $121.65 to $124.79. The transaction was conducted pursuant to a pre-arranged 10b5-1 trading plan adopted on 2026-03-02, meaning this was a scheduled sale rather than a discretionary decision. Post-transaction, Peetz retains 194,309 shares (194.3K shares) of common stock and holds 108,487 in-the-money employee stock options, preserving substantial equity exposure. Notably, his prior trades at this ticker across five sales on 2026-06-01 have shown 30-day returns ranging from 20.9% to 27.3%, suggesting the stock has had strong momentum—the current price of $128.57 is only 0.3% below the 52-week high despite the blended sale price averaging $122.27. The company remains unprofitable (net income of $-790.2M in the latest full fiscal year) despite significant revenue growth of 54.7% annually, indicating execution risk persists despite recent stock appreciation.

CEO Peetz sells 30,000 shares ($2.9M) via scheduled 10b5-1 plan; retains 194,309 shares plus 128,487 stock options

Christopher Peetz executed 6 separate sales totaling 30,000 shares for $2,875,103.34 at prices ranging from $94.64 to $99.66, reducing his non-derivative holdings from 224,309 to 194,309 shares (-13.4%). This transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2026-03-02, making it scheduled rather than discretionary. The sales occurred as the stock trades at $92.17, down 19.8% from its 52-week high of $114.99, though it is up 30 days (-4.5%) and up 90 days (-0.9%). At MIRM specifically, Peetz's prior 5 sales show mixed near-term outcomes: his most recent sale on 2026-03-16 was followed by 30-day and 90-day gains of 4.8% and 4.7% respectively, while his 2026-02-02 sale saw subsequent declines of 9.9% and 6.6%. The company remains unprofitable (net income of $-790,155,000.00 in the most recent period) despite annual revenue growth of +54.7%, reflecting an early-stage or turnaround profile.

Director Patrick J Heron buys 131,425 MIRM shares for $8,999,984 at $68.48; stock now at $99.27, up 25.2% in 30 days

Patrick J Heron, a director of Mirum Pharmaceuticals, purchased 131,425 shares at $68.48 on 2026-01-23, expanding his holdings by 40.1% to 459,010 shares total with a transaction value of $8,999,984.00. The stock has since rallied to $99.27, representing 25.2% appreciation in just 30 days and 40.9% over 90 days, approaching the 52-week high. Critically, Heron's prior 5 open-market purchases at MIRM (all in March 2025) demonstrated a consistent pattern: each buy was followed by positive 90-day returns ranging from +7.0% to +13.0%, establishing a 100% win rate at this specific ticker on the 90-day timeframe. Against this backdrop of sustained revenue growth of 80.8% year-over-year and a substantial director stake accumulation, this large, discretionary purchase signals conviction in Mirum's trajectory, though the company remains unprofitable on a full-year basis despite recent quarterly profitability of $2.9M.

Director Michael G Grey sells entire 50,000-share position at $78.00 (10b5-1 plan)

GREY MICHAEL G, a Director at Mirum Pharmaceuticals, liquidated his complete 50.0K-share holding on 2025-12-19 at $78.00 per share, generating $3.9M in proceeds. The transaction was executed under a 10b5-1 trading plan adopted on 2025-08-22, meaning it was scheduled and automatic rather than discretionary. Full elimination of a director's stake is a notable structural change in insider ownership. The pre-arranged nature of the trade removes timing-based inference, but the magnitude—100.0% exit from his holdings—is material enough to warrant investor attention regarding any changes in board engagement or confidence signals typically conveyed by residual ownership.

Director Michael G Grey sells entire 50,000-share position (100% of holdings) in MIRM for $3.7M under 10b5-1 plan adopted 2025-08-22

Director Michael G Grey liquidated his complete shareholding of 50,000 shares at $74.00 on 2025-12-01, eliminating his position entirely. The sale was executed under a pre-arranged 10b5-1 trading plan adopted on 2025-08-22, meaning the transaction followed a scheduled formula rather than a discretionary decision at the time of sale. Complete director equity exit raises questions about ongoing commitment and confidence, though the pre-planned nature prevents attribution to market timing or recent company developments. The $3,700,000.00 proceeds represent full liquidation of a director-level stake.

Director Michael G Grey sells all 50,000 shares of MIRM for $3.5M via scheduled 10b5-1 plan

Michael G Grey, a Director, sold 50,000 shares (50.0K shares) of Mirum Pharmaceuticals at $70.00 on 2025-11-21 for a total value of $3,500,000.00 ($3.5M), reducing his holdings to 0 shares post-transaction. This represents a complete exit from his equity position (-100.0% vs pre-transaction holdings). The transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2025-08-22, meaning it was scheduled and not discretionary. While a complete director departure from equity ownership is noteworthy, the pre-arranged nature of the plan indicates this sale was determined months in advance rather than driven by current market conditions or near-term business developments.

Director Laura Brege sells 17,000 shares (52.0% of holdings) at $74.40 avg, reducing stake from 32,703 to 15,703 shares

Laura Brege, a director of Mirum Pharmaceuticals, executed two separate sales on 2025-09-11 totaling 17,000 shares for $1,264,868.43, reducing her holdings by 52.0%. The sales occurred at prices of $74.34 and $75.07, near the current price of $74.31 and within the 52-week range of $37.85–$77.69. Notably, Mirum reported revenue of $127,785,000.00 in its latest quarter with strong annual revenue growth of +80.8%, but the company remains unprofitable with net income of $-5,861,000.00 in its most recent quarter. This substantial reduction in the director's stake warrants examination of whether the sale reflects conviction about near-term valuation levels or operational performance, particularly given the company's growth trajectory offset by persistent losses.

CEO Peetz Christopher sold 40,000 shares of MIRM at $62.00 on 2025-08-11; stock now at $64.72, down from 52-week high of $65.87.

Christopher Peetz, MIRM's CEO, sold 40,000 shares (40.0K shares) for $2,480,000.00 on 2025-08-11, reducing his holdings by 22.4% to 138,641 shares. The sale occurred near the company's 52-week highs ($65.87), with the stock currently trading at $64.72, -1.8% from that peak. Despite near-term weakness and a 30-day return of -6.8% on his cross-ticker sales historically, MIRM itself has rallied +22.9% over 30 days and +45.8% over 90 days post-announcement, placing this sale at a notably inopportune exit point relative to subsequent price action. The company remains unprofitable (net income $-5.9M) despite strong annual revenue growth of +80.8%, and Peetz's prior three measurable sales at MIRM show 2 of 3 were well-timed at the 90-day mark, making this sale's departure from that pattern noteworthy for investors monitoring management conviction.

CEO Christopher Peetz sells 40,000 MIRM shares at $55.25 via 10b5-1 plan adopted Nov 2024

Christopher Peetz, the CEO, sold 40,000 shares on 2025-08-07 at $55.25 per share under a pre-arranged 10b5-1 trading plan adopted on 2024-11-22. This is a scheduled transaction, not a discretionary trade, reducing his holdings from 178,641 shares to 138,641 shares, a reduction of 22.4%. Since the sale is governed by a pre-arranged plan, it reflects predetermined liquidity management rather than a discretionary market-timing decision. The magnitude of the sale—22.4% of pre-transaction holdings—represents a material reduction in his direct stake, which merits monitoring for its effect on CEO alignment with shareholder interests.